Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions reports developments tied to its biotechnology platforms for producing precision-engineered recombinant proteins and enzymes. The company uses proprietary microbial expression systems, including C1 and Dapibus, to serve life sciences, food and nutrition, and industrial biotechnology applications through product sales, licensing, and partner commercialization.
Recurring news includes financial results, corporate update calls, commercial launches, distribution agreements, and development collaborations. Company updates have covered recombinant human albumin, animal-origin-free recombinant DNase I, transferrin, bovine alpha-lactalbumin, non-animal dairy enzymes, and broader portfolios for cell culture, molecular biology, nutrition, and bioindustrial markets.
Dyadic International (NASDAQ: DYAI) entered into definitive agreements with an institutional investor for a registered direct offering of Common Stock and a concurrent private placement of warrants, expected to generate aggregate gross proceeds of approximately $2.9 million.
The company will sell 3,625,000 Common shares at $0.795 per share and issue Common Warrants to purchase 3,625,000 shares at an exercise price of $0.84 per share, with each Warrant priced at $0.005. Closing is expected on or about August 14, 2026, subject to customary conditions. Dyadic plans to use net proceeds, along with existing cash and investment-grade securities, for general corporate purposes and working capital. Aegis Capital is acting as exclusive placement agent. The stock offering is made under an effective Form S-3 shelf registration, while the warrants are offered via a private placement to accredited investors, with related resale registration rights.
Dyadic Applied BioSolutions (NASDAQ: DYAI) reported Q2 2026 revenue of $961,138, essentially flat year over year, as lower research and development and milestone revenue were offset by higher CEPI and Gates Foundation grant revenue. Cash, cash equivalents, restricted cash and investment-grade securities totaled $4.8 million at June 30, 2026, down from $8.6 million at year-end 2025.
Cost of revenue rose 60.4% to $984,165, while R&D expenses fell 47.2% and G&A expenses increased 17.6%. Loss from operations widened to $2.1 million and net loss to $2.1 million, or $(0.06) per share. Dyadic highlighted advancing commercial shipments, new dairy-protein and cultivated-meat collaborations, and progress in Gates Foundation-, CEPI- and NIAID-supported antibody and vaccine programs using its C1 platform.
Dyadic (Nasdaq: DYAI) announced a new development and commercial license agreement with a European biotechnology company to expand its non-animal, precision-fermented dairy protein pipeline. The collaboration targets additional dairy proteins intended for a broad range of food and nutrition applications.
The agreement aligns with Dyadic's strategy to generate recurring revenue through development partnerships, licensing and commercial participation. According to Dyadic, it is eligible for development and commercial payments, licensing-related revenues and other economic participation tied to successful commercialization.
The program builds on Dyadic's existing Dapibus™-enabled initiatives, including commercial recombinant bovine chymosin with Inzymes ApS and development of bovine alpha-lactalbumin with BRIG BIO, reinforcing Dapibus™ as a scalable precision fermentation platform for commercial dairy proteins and enzymes.
Dyadic (Nasdaq: DYAI) plans to report its Q2 2026 financial results and host a corporate update conference call on Wednesday, August 12, 2026, at 5:00 p.m. Eastern Time. Investors can join via toll-free and international dial-in numbers or a live webcast, with a replay available on Dyadic's investor relations website.
Dyadic (Nasdaq: DYAI) reported that, in approximately 15 days after receiving plasmids, it developed stable pools of C1 cell lines and manufactured and initially purified two Scripps-designed Bundibugyo ebolavirus recombinant protein antigens. The C1-produced antigens have been delivered to Fondazione Biotecnopolo di Siena and Scripps Research for preclinical evaluation in support of a potential non-mRNA Bundibugyo ebolavirus vaccine candidate.
According to Dyadic, this rapid turnaround highlights the C1 platform’s potential to accelerate development of vaccines, monoclonal antibodies and other biologics. The company notes C1’s scalability, high antibody titers exceeding 12 g/L in seven days, and the completed receipt of a $3.1 million Gates Foundation grant supporting monoclonal antibody programs.
Dyadic (Nasdaq: DYAI) announced that Nasdaq has confirmed the company has regained compliance with Nasdaq Listing Rules 5550(a)(2) and 5550(b), and its common stock will continue to be listed and traded on The Nasdaq Capital Market.
According to Dyadic, resolving the continued listing matter provides greater stability as it focuses on executing its business strategy, including developing and commercializing its own products, expanding adoption of its C1 and Dapibus™ protein production platforms, advancing strategic collaborations and pursuing long-term shareholder value.
Dyadic Applied BioSolutions (Nasdaq: DYAI) announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program targeting advanced cellulose processing. The initiative builds on the commercialization of EN3ZYME™ and further showcases the scalability and repeatability of Dyadic’s Dapibus™ microbial expression platform.
The newly developed enzyme is intended for applications including pulp biorefining, microcrystalline cellulose and nanocellulose production. According to Dyadic, the program addresses a multi-billion-dollar industrial enzyme market and supports a dual commercialization model spanning proprietary product sales, strategic partnerships, contract manufacturing and technology licensing, as it advances through optimization, pilot-scale production and customer evaluation.
Dyadic (Nasdaq:DYAI) reported continued global collaborations validating its C1 protein production platform and expanding its commercial path.
C1-based monoclonal antibodies for RSV and malaria are fully funded by a $3.1 million Gates Foundation grant, while a $4.5 million CEPI/FBS collaboration has shown plasmid-to-purified-protein production in about 15 days. Dyadic targets an estimated $25 billion addressable biologics manufacturing opportunity through partner-funded programs, licensing, and commercial manufacturing.
Dyadic (Nasdaq: DYAI) announced that the Japan Patent Office has allowed claims covering its proprietary Thermothelomyces heterothallica recombinant protein expression technology. This strengthens its global IP portfolio and supports Dyadic’s C1 and Dapibus™ microbial production platforms.
Dyadic is also expanding business development in Japan through Intralink, with meetings planned in early July across multiple life science and industrial sectors.
Dyadic (Nasdaq: DYAI) reports rising interest in its C1 microbial protein platform amid Bundibugyo Ebola preparedness and broader commercialization. The platform has progressed from viral gene sequence to purified antigen or monoclonal antibody in about 15 days, which Dyadic views as important for outbreak response.
According to the company, C1 is being evaluated in three Ebola-related tracks with Scripps Research, CEPI-focused proposals, and an initiative with Fondazione Biotecnopolo di Siena and the European Vaccines Hub. Dyadic also highlights commercial launches of C1- and Dapibus-produced proteins across biopharma, life sciences, food, nutrition and industrial markets.